Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing ...

Jazz Pharma has agreed to pay $145 million to settle lawsuits claiming it illegally acted to prevent generic versions of its ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in ...

Xyrem (sodium oxybate) may not be safe to take while pregnant or breastfeeding. Certain factors, including the risk of not treating your condition during pregnancy, may determine whether you ...

Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin ...

Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, ...

Xyrem, a medication approved in the U.S., is used for the treatment of excessive daytime sleepiness and sudden loss of muscle control in patients suffering from narcolepsy, a chronic neurological ...

Subject to court approval, the settlement will bring an end to class action lawsuits initiated by several Xyrem buyers who accused Ireland-based Jazz (NASDAQ:JAZZ) of reaching illegal patent ...